Genzyme’s Second Quarter Earnings Statement

Jul 23, 2009 | NEWS

In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the US LumizymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More application. To...

Changing Lives—UTSA Sombrilla

Jul 20, 2009 | EDITORIALS

By: Jason B. Johnson posted on: July 20, 2009 Published in University of Texas San Antonio’s Sombrilla Magazine: Summer 2009 Tiffany House was just 11 when she was diagnosed with a rare and often fatal disease called Acid Maltase Deficiency. Doctors told her she...

Genzyme Submits All Information Requested by FDA for Lumizyme

May 22, 2009 | NEWS

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has submitted the final documentation to address all items in the FDA’s complete response letter for LumizymeTM (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe...

IPA Statement: The End Of Myozyme Supply Restrictions

May 8, 2009 | EDITORIALS

By: IPA posted on: May 08, 2009 Dear IPA Affiliate, You will no doubt have heard the wonderful news that MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More from the Belgian production facility has been...

IPA Statement: The End of Myozyme Supply Restrictions

May 8, 2009 | NEWS

Dear IPA Affiliate, You will no doubt have heard the wonderful news that MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More from the Belgian production facility has been approved for patients within the...

Pompe Program Update from Genzyme

Mar 3, 2009 | NEWS

Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global supply of Myozyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of...

Genzyme Receives Positive Opinion on Myozyme from CHMP

Feb 19, 2009 | NEWS

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s variation to produce Myozyme® (alglucosidase alfaA form of enzyme replacement therapy...